Frontier Biotechnologies's quarterly market cap
increased
from Sep. 2025 (¥5,405.2 Mil) to Dec. 2025 (¥6,761.2 Mil) and
increased
from Dec. 2025 (¥6,761.2 Mil) to Mar. 2026 (¥7,098.3 Mil).
Frontier Biotechnologies's annual market cap
declined
from Dec. 2023 (¥3,715.8 Mil) to Dec. 2024 (¥3,655.9 Mil) but then
increased
from Dec. 2024 (¥3,655.9 Mil) to Dec. 2025 (¥6,761.2 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Frontier Biotechnologies's Enterprise Value for Today is ¥10,087.7 Mil.
Frontier Biotechnologies (SHSE:688221) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Frontier Biotechnologies Market Cap Related Terms
Frontier Biotechnologies Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Frontier Biotechnologies's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Frontier Biotechnologies Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Frontier Biotechnologies's Market Cap distribution charts can be found below:
* The bar in red indicates where Frontier Biotechnologies's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Frontier Biotechnologies's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Frontier Biotechnologies (SHSE:688221) has a Market Cap of ¥10,345.9 Mil as of Jul. 06, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Frontier Biotechnologies and its competitors. According to the industry distribution chart, Frontier Biotechnologies ranks #197 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 19.2%.
Is Frontier Biotechnologies' Market Cap too high?
Frontier Biotechnologies' current Market Cap is ¥10,345.9 Mil. Based on the distribution chart, Frontier Biotechnologies ranks #197 out of 1024 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Frontier Biotechnologies has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Frontier Biotechnologies' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Frontier Biotechnologies ranks #197 out of 1024 companies for Market Cap. This places Frontier Biotechnologies in the top 19% of its industry — outperforming the majority of peers. The industry median Market Cap is 214.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 214.89, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Frontier Biotechnologies and its competitors. For the Drug Manufacturers industry, the median Market Cap is 214.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Frontier Biotechnologies's current Market Cap is ¥10,345.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Frontier Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Frontier Biotechnologies (SHSE:688221) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥37.29, compared to a current price of ¥27.62 — trading 25.9% below its estimated fair value. The current Market Cap is ¥10,345.9 Mil. Frontier Biotechnologies' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Frontier Biotechnologies (SHSE:688221), the current Market Cap is ¥10,345.9 Mil as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Frontier Biotechnologies (SHSE:688221) Overvalued in 2026?
Based on GuruFocus' analysis, Frontier Biotechnologies stock appears to be undervalued.
The current stock price of ¥27.62 is trading 25.9% below its estimated GF Value™ of ¥37.29.
GuruFocus considers Frontier Biotechnologies to be Modestly Undervalued.
Key valuation signals for SHSE:688221:
Market Cap: ¥10,345.9 Mil
GF Value™: ¥37.29 vs. price of ¥27.62 (25.9% below fair value)
No single metric tells the full story. See the SHSE:688221 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688221 has been successfully added to your 
